List of Excipients in Branded Drug DICYCLOMINE

Generic Drugs Containing DICYCLOMINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0143-1227	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0143-1227	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0143-1227	FD&C BLUE NO. 1
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0143-1227	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0143-1227	MAGNESIUM STEARATE
NCS HealthCare of KY LLC dba Vangard Labs	dicyclomine hydrochloride	0615-0327	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY LLC dba Vangard Labs	dicyclomine hydrochloride	0615-0327	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in DICYCLOMINE?

# Of NDCs	Excipient
11	ANHYDROUS LACTOSE
14	CELLULOSE, MICROCRYSTALLINE
13	FD&C BLUE NO. 1
1	FD&C RED NO. 4
1	FD&C RED NO. 40
3	GELATIN
14	LACTOSE MONOHYDRATE

Last updated: August 8, 2026

Executive summary: Dicyclomine is a mature, low-cost anticholinergic used for functional bowel and irritable bowel syndrome symptoms. Its core molecule has no meaningful remaining composition-of-matter exclusivity, and U.S. products are primarily generic oral capsules, tablets, solutions, and injectable products. Commercial opportunity is therefore concentrated in excipient-led differentiation: alcohol-free and sugar-free liquids, taste-masked oral products, preservative-free unit doses, stable ready-to-use presentations, and supply-secure generic products. A new formulation would face limited patent barriers but would need a clear FDA pathway, bioequivalence strategy, and safety controls for anticholinergic effects and pediatric use.

Dicyclomine Excipient Strategy and Commercial Opportunities

What is the commercial position of dicyclomine?

Dicyclomine hydrochloride is an anticholinergic and antispasmodic approved for the treatment of functional bowel and irritable bowel syndrome symptoms. In the United States, the reference product is Bentyl, historically marketed by Aptalis and now supplied through generic manufacturers. FDA-approved dosage forms include oral capsules, tablets, oral solution, and intramuscular injection.[1]

The product is commercially mature:

Attribute	Dicyclomine position
Active ingredient	Dicyclomine hydrochloride
Primary use	Functional bowel and irritable bowel syndrome symptoms
Main U.S. dosage forms	10 mg and 20 mg capsules or tablets; 10 mg/5 mL oral solution; 20 mg/2 mL injection
Regulatory pathway for most competitors	Abbreviated New Drug Application, or ANDA
Product type	Small-molecule generic
Biologic or biosimilar exposure	None
Core patent position	No meaningful current composition-of-matter exclusivity identified
Main differentiation opportunity	Excipients, dosage form, packaging, supply reliability, and patient usability
Key safety constraint	Anticholinergic adverse effects and serious risk in young infants

The mature market limits pricing power for conventional immediate-release capsules and tablets. Differentiated products can still compete where they solve formulation or access problems, especially for patients who cannot swallow tablets, caregivers administering liquid doses, hospitals managing injectable stock, and pharmacies seeking reliable generic supply.

What excipients are used in dicyclomine products?

Dicyclomine products use different excipient systems by manufacturer and dosage form. The applicable inactive ingredients are product-specific and should be confirmed against the current FDA labeling and FDA Inactive Ingredient Database before development.[2,3]

Oral capsules

Immediate-release capsules generally require:

• A diluent or filler
• A disintegrant
• A lubricant or glidant
• Capsule-shell gelatin
• Colorants or opacifiers
• Potentially a wetting agent or surfactant

The principal technical risks are content uniformity at relatively low dose, capsule fill consistency, dissolution, and compatibility with gelatin shells. Dicyclomine hydrochloride is used at 10 mg and 20 mg strengths, so the formulation must control low-dose blend uniformity across commercial-scale batches.

A conventional hard-gelatin capsule is difficult to defend through formulation patents unless it incorporates a distinct release profile, stability solution, or delivery technology. The stronger commercial argument is usually lower cost, consistent supply, or a more convenient strength combination.

Tablets

Immediate-release tablets may use lactose, microcrystalline cellulose, starch, croscarmellose sodium, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, coatings, and colorants, depending on the manufacturer. A tablet formulation should prioritize:

• Rapid disintegration
• Robustness during packaging and transport
• Low friability
• Consistent dissolution
• Low moisture sensitivity
• Compatibility with high-speed compression

Film coating can improve swallowability, reduce dust, mask bitterness, and distinguish the product visually. Coating alone is unlikely to create a strong patent position unless it is part of a non-obvious stability or taste-masking system.

Oral solution

The oral solution offers the clearest excipient-led opportunity. Liquid products can be designed around:

• Purified water
• Sweeteners
• Buffering agents
• Preservatives, where justified
• Viscosity modifiers
• Flavor systems
• Chelating agents
• Solubilizers or cosolvents
• pH-control agents

The main development issues are chemical stability, microbial control, taste, dosing accuracy, and packaging compatibility. Dicyclomine has a pronounced bitter and anticholinergic taste profile, making flavoring alone potentially inadequate. A combined strategy using bitterness suppression, controlled pH, viscosity adjustment, and a compatible sweetener system may provide a more reliable patient experience.

A sugar-free product could target diabetic patients, institutional formularies, and caregivers who prefer lower-carbohydrate formulations. Polyol systems such as sorbitol or other sugar substitutes may introduce gastrointestinal tolerability concerns, which is particularly relevant for a drug used to treat gastrointestinal symptoms. The formulation should therefore avoid creating a new laxative or bloating burden through excessive polyol loading.

An alcohol-free oral solution could also have commercial value. Some legacy liquid formulations use cosolvents or flavor systems that may be undesirable for children, older adults, or patients with alcohol-avoidance requirements. The product label must clearly describe the excipient composition and dosing limitations.

Injectable solution

Dicyclomine injection is an intramuscular product. The FDA label states that the injection is not for intravenous administration and is contraindicated in infants younger than six weeks.[1] The product requires strict control of:

• Sterility
• Endotoxin
• Particulate matter
• pH
• Osmolality
• Container closure integrity
• Extractables and leachables
• Preservative concentration, if used

A preservative-free, single-dose presentation may appeal to hospitals and ambulatory settings, especially where multidose-vial handling creates operational concerns. The trade-off is higher packaging cost and potentially shorter post-opening use flexibility.

What excipient strategy is strongest for dicyclomine?

The strongest strategy is a portfolio rather than a single formulation.

Product concept	Commercial rationale	Main technical barrier	Likely regulatory route
Generic 10 mg and 20 mg capsules	Lowest-cost market entry	Blend uniformity and dissolution	ANDA
Film-coated tablets	Better swallowability and visual differentiation	Coating robustness and bioequivalence	ANDA
Sugar-free oral solution	Caregiver and institutional utility	Taste, microbial control, polyol tolerability	ANDA or 505(b)(2), depending on differences
Alcohol-free oral solution	Patient and formulary differentiation	Solubility, flavor, stability	ANDA or 505(b)(2)
Taste-masked liquid	Improved adherence	Masking without delaying absorption	ANDA or 505(b)(2)
Preservative-free injection	Hospital and safety positioning	Sterility and packaging economics	ANDA or 505(b)(2)
Unit-dose oral liquid	Dosing accuracy and institutional use	Packaging cost and stability	ANDA or 505(b)(2)
Modified-release product	Potentially fewer daily doses	Clinical benefit and pharmacokinetic bridging	Likely 505(b)(2) or NDA
Orally disintegrating tablet	Swallowing convenience	Taste and friability	ANDA or 505(b)(2)

A standard liquid generic has the largest practical opportunity because it can address dosing and swallowing limitations without requiring a new therapeutic claim. A modified-release product has greater differentiation potential but also materially higher clinical, regulatory, and patent-development risk.

What formulation patents protect dicyclomine products?

Publicly available U.S. Orange Book information does not indicate a meaningful active patent estate protecting conventional dicyclomine capsules, tablets, oral solution, or injection products.[4] The commercial landscape is therefore driven primarily by generic approval, manufacturing capability, and product execution rather than by blocking patents.

Potentially protectable features for a new product could include:

• A defined pH and buffer system that improves stability
• A specific taste-masking matrix
• A preservative-free sterile presentation
• A novel unit-dose container
• A controlled-release multiparticulate system
• A combination of excipients that improves dissolution or content uniformity
• A packaging system that limits moisture or light exposure

Patentability would depend on unexpected technical results, not simply the selection of common pharmaceutical excipients. Broad claims covering a dicyclomine formulation would face prior-art risk because immediate-release oral products and standard liquid excipient systems are well established.

When does dicyclomine lose exclusivity?

Dicyclomine’s original small-molecule exclusivity and early product patents expired decades ago. The product is now in the generic phase, with multiple manufacturers supplying the U.S. market. Current commercial exclusivity does not depend on a live composition-of-matter patent.

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
Composition-of-matter patent	No current blocking right identified
Reference-product exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current commercial relevance identified
Biosimilar exclusivity	Not applicable
Formulation or method-of-use exclusivity	No material Orange Book barrier identified for conventional products

Patent expiry should not be confused with the expiry of a particular manufacturer’s manufacturing know-how, trade secrets, trademarks, or private contractual rights. Those rights may affect competition without creating an FDA-listed patent block.

What is the Orange Book status of dicyclamine?

The FDA Orange Book lists approved drug products and patent or exclusivity information relevant to generic substitution. Dicyclomine products are generally positioned as multisource generic products rather than as products protected by active Orange Book patents.[4]

The Orange Book analysis has four implications:

1. A conventional dicyclomine ANDA does not typically face a listed-patent certification dispute comparable to a still-protected branded product.
2. Paragraph IV litigation risk is comparatively low for an unprotected immediate-release product.
3. A new formulation with meaningful clinical or delivery differences may require a 505(b)(2) strategy rather than a simple ANDA.
4. A developer should not assume that a formulation patent will automatically create an Orange Book barrier. Listing eligibility depends on statutory and regulatory requirements.

Are there Paragraph IV challenges or dicyclomine patent lawsuits?

Dicyclomine is not associated with a current, high-profile Paragraph IV litigation campaign involving a blocking branded patent estate. The drug’s mature generic status reduces the probability of a conventional first-filer patent contest.

Litigation risk could reappear if a sponsor commercializes:

• A new extended-release formulation
• A novel liquid or taste-masked formulation
• A combination product
• A device-enabled delivery system
• A formulation with a separately listed method of use

Those products could generate disputes over patent validity, infringement, obviousness, written description, enablement, or the proper ANDA versus 505(b)(2) pathway. A new entrant would also need to manage trademark, trade dress, false advertising, and state substitution issues even where patent risk is limited.

What FDA regulatory status applies to a new dicyclomine formulation?

A conventional product that matches the reference listed drug in active ingredient, dosage form, strength, route, labeling, and performance may qualify for an ANDA. FDA bioequivalence and pharmaceutical-equivalence requirements remain central.[5]

A 505(b)(2) application may be more appropriate where the product introduces a clinically meaningful difference, such as:

• Modified release
• A new route of administration
• A new dosage form not adequately covered by the reference product
• A novel delivery device
• A new formulation requiring reliance on published safety or efficacy information

Excipient changes do not automatically require a 505(b)(2) application. The regulatory route depends on whether the change preserves the relevant reference-product attributes and whether the product can satisfy ANDA requirements.

FDA review would focus on:

• Assay and impurities
• Dissolution
• Stability
• Bioequivalence
• Microbial limits for oral liquids
• Sterility and endotoxin for injections
• Extractables and leachables
• Labeling consistency
• Human factors for dosing devices

What pediatric and safety constraints affect excipient selection?

The dicyclomine label contains important age-related restrictions. Dicyclomine is contraindicated in infants younger than six weeks, and reports describe serious respiratory and neurologic adverse events in infants.[1] This limits the commercial value of positioning a product as a general pediatric antispasmodic.

Excipient strategy should account for:

• Avoiding unnecessary alcohol in liquid products
• Controlling benzyl alcohol and other potentially problematic preservatives
• Providing an accurate oral syringe rather than a household-spoon dosing instruction
• Limiting excipients that cause gastrointestinal discomfort
• Avoiding high-sugar formulations where institutional or chronic-use concerns apply
• Ensuring child-resistant packaging where required
• Providing clear warnings against use in infants below the labeled age threshold

The product should be designed for appropriate adult and older-pediatric use, not marketed in a way that implies unrestricted infant use.

Which companies are challenging the dicyclomine market?

Competition is primarily from generic manufacturers and distributors rather than from a branded innovator defending exclusivity. Market participants can include vertically integrated generic companies, contract manufacturers, specialty pharmaceutical distributors, and private-label suppliers.

Competitive differentiation is likely to arise from:

• FDA-approved supply continuity
• Dual-source manufacturing
• Shorter lead times
• Hospital contract pricing
• Reliable oral-solution availability
• Packaging suitable for retail and institutional channels
• Low minimum order quantities
• Ability to maintain multiple strengths and dosage forms

Because the active ingredient is mature and inexpensive, a manufacturer with a dependable API source and efficient packaging operation may compete effectively without owning a novel patent.

What revenue exposure and commercial opportunities exist?

Dicyclomine revenue is difficult to isolate because generic sales are fragmented across manufacturers, wholesalers, retail pharmacies, Medicaid programs, and institutional contracts. Public company filings generally do not report dicyclomine as a standalone material product line.

The most attractive opportunities are likely:

High opportunity

• Sugar-free, alcohol-free oral solution
• Taste-masked liquid with an accurate dosing syringe
• Consistently available 10 mg and 20 mg capsules
• Unit-dose liquid or capsule packaging for institutional use
• Preservative-free injection where procurement supports a premium

Moderate opportunity

• Orally disintegrating tablet
• Film-coated tablet with improved swallowability
• Private-label product for pharmacy or telehealth channels
• Combination packaging containing multiple strengths

Lower opportunity

• Conventional uncoated tablet
• Another undifferentiated capsule
• Modified-release product without clear adherence or clinical benefit
• Premium pricing based only on color, flavor, or packaging

A differentiated liquid can command better commercial positioning than a standard capsule, but the market remains price-sensitive. The business case should be based on incremental gross margin, supply reliability, and channel access rather than a large branded-drug premium.

How does dicyclamine compare with competing antispasmodics?

Dicyclomine competes with other symptom-directed products, including hyoscyamine, peppermint-oil products, and non-anticholinergic approaches used for irritable bowel syndrome. The comparison is commercial as much as pharmacological.

Product category	Main differentiation	Excipient opportunity	Commercial constraint
Dicyclomine	Established anticholinergic antispasmodic	Liquid taste masking, preservative strategy, unit dose	Generic price pressure
Hyoscyamine	Anticholinergic antispasmodic with multiple dosage forms	Sublingual and orally disintegrating formats	Similar anticholinergic tolerability issues
Peppermint oil	Non-anticholinergic symptom approach	Enteric coating and odor control	Different evidence and labeling profile
IBS-specific branded therapies	Disease-specific labeling and newer mechanisms	Advanced delivery and patient-support packaging	Higher development and reimbursement risk

Dicyclomine’s advantage is familiarity and low acquisition cost. Its weakness is limited differentiation and a safety profile that constrains broad patient positioning.

What manufacturing and intellectual-property barriers remain?

The API itself is not the main barrier. Manufacturing barriers are more likely to involve:

• API qualification and supply continuity
• Impurity controls
• Low-dose blend uniformity
• Oral-liquid microbial control
• Taste-masking reproducibility
• Sterile manufacturing for injection
• Container-closure qualification
• Scale-up of suspending or viscosity-modifying systems
• Stability through the labeled shelf life

Trade secrets may protect process parameters, excipient order of addition, flavor systems, or packaging controls. Those protections can support commercial differentiation but do not provide the same exclusionary power as a valid patent.

Geographic coverage is also important. U.S. ANDA approval does not establish rights in Europe, Canada, Japan, or emerging markets. Each jurisdiction may require separate registration, local bioequivalence documentation, pharmaceutical-quality compliance, and country-specific labeling. A formulation patent would require separate national filings and would face different patentability and listing rules.

Key Takeaways

• Dicyclomine is a mature generic drug with no meaningful current composition-of-matter exclusivity.
• Conventional capsules and tablets offer limited opportunity beyond cost, availability, and channel execution.
• Oral liquids provide the strongest excipient-led differentiation opportunity.
• Sugar-free, alcohol-free, taste-masked, and unit-dose liquid products have the clearest commercial logic.
• Injectable opportunities center on preservative-free packaging, sterility assurance, and hospital supply reliability.
• A standard formulation should generally be evaluated for an ANDA; meaningful delivery or clinical changes may require a 505(b)(2) application.
• Paragraph IV and Orange Book patent risks are limited for conventional dicyclamine products.
• Any formulation patent would need credible technical advantages over routine excipient selection.
• Pediatric positioning requires strict attention to the six-week infant contraindication and excipient safety.
• Revenue exposure is fragmented and generally not separately disclosed, so commercial success depends on supply, procurement access, and formulation usability.

FAQs

Can dicyclomine be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could improve administration for patients who have difficulty swallowing. Taste masking, moisture protection, mechanical strength, and rapid dissolution would be the main development issues.

Is a sugar-free dicyclomine liquid commercially viable?

Yes, particularly for institutional, caregiver, and selected adult-patient channels. The formulation must avoid excessive polyol content that could worsen gastrointestinal symptoms.

Can a new dicyclomine formulation obtain patent protection?

Possibly, but routine use of conventional excipients is unlikely to support strong claims. Patent value would depend on unexpected stability, taste, dissolution, delivery, or manufacturing results.

Does dicyclomine have biosimilar competition?

No. Dicyclomine is a synthetic small molecule, so competition proceeds through generic-drug pathways rather than biosimilar regulation.

What is the most defensible dicyclomine product concept?

A stable, alcohol-free and sugar-free oral solution with effective bitterness control, an oral dosing syringe, child-resistant packaging, and reliable multi-channel supply is the most practical differentiated concept.

References

1. U.S. Food and Drug Administration. (n.d.). Dicyclomine hydrochloride prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
3. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry.